The design and development of imidazothiazole-chalcone derivatives as potential anticancer drugs

Expert Opinion on Drug Discovery

Volumn 8, Issue 3, 2013, Pages 289-304

  Kamal, Ahmed ^a   Kashi Reddy, Methuku ^a   Viswanath, Arutla ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Anticancer activity; Chalcones and imidazothiazole chalcone conjugates and chemotherapeutic agents; Imidazothiazoles

Indexed keywords

1 INDOLYL 3 PHENYLPROPENONE DERIVATIVE; 3 (5 IMIDAZO[2,1 B]THIAZOLYLMETHYLENE) 2 INDOLINONE DERIVATIVE; 3 INDOLYL 1 PHENYLPROPENONE DERIVATIVE; 3,5 BIS(2 FLUOROBENZYLIDENE) 4 PIPERIDINONE; ALPHA METHYLCHALCONE; ANTINEOPLASTIC AGENT; BENZIMIDAZO[2,1 B]THIAZOLE GUANYLHYDRAZONE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CHALCONE DERIVATIVE; COMBRETASTATIN A4; CURCUMIN; CYTOTOXIC AGENT; FLAVOKAWAIN A; IMIDAZO[2,1 B]THIAZOLE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOLIQUIRITIGENIN; LEVAMISOLE; LICOCHALCONE A; NATURAL PRODUCT; ORNITHINE DECARBOXYLASE; OXYGENASE INHIBITOR; POLYAMINE; PYRIMIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; SD 400; THIAZOLE DERIVATIVE; TRIHYDROXYCHALCONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOHUMOL;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CHEMICAL MODIFICATION; COLON CANCER; CONJUGATE; CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; G2 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK CANCER; HELMINTHIASIS; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHALCONE; DRUG DESIGN; HUMANS; IMIDAZOLES; THIAZOLES;

EID: 84874372655     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.758630     Document Type: Review

References (89)

1. Garcia M, Jemal A, Ward EM, et al. Global cancer facts & figures 2007. American Cancer Society, Atlanta, GA; 2007
2. World Health Organization. Data and statics. Available from: http://www.who. int/research/en
3. Donna SS. Introduction to cancer chemotherapeutics. Chem Rev 2009;109:2859-61
4. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48:6523-43
5. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641-51
6. Michael AF, Brent RS, Curtis TK, et al. Systematic discovery of multicomponent therapeutics. PNAS 2003;100:7977-82
7. Meunier B. Hybrid molecules with a dual mode of action: dream or reality. Acc Chem Res 2008;41:69-77
8. Fenichel RI, Chirigos MA, Hoerig CH, et al. immune modulation agents and their mechanism. Marcel Dekker Inc NY-Basel 1984;383-08
9. Andreani A, Leoni A, Locatelli A, et al. Potential antitumor agents. part 291: synthesis and potential coanthracyclinic activity of imidazo[2,1-b] thiazole guanylhydrazones. Bioorg Med Chem 2000;8:2359-66
10. Andreani A, Granaiola M, Leoni A, et al. Effects of new ubiquinone-imidazo[2,1-b] thiazoles on mitochondrial complex I (NADH-ubiquinone reductase) and on mitochondrial permeability transition pore. Bioorg Med Chem 2004;12:5525-32
11. Andreani A, Burnelli S. Granaiola MA, et al. New Antitumor Imidazo[2,1-b] thiazole Guanylhydrazones and Analogues. J Med Chem 2008;51:809-16
12. Andreani A, Burnelli S, Granaiola M, et al. Antitumor activity of new substituted3-(5-imidazo[2,1-b] thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b] thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events. J Med Chem 2008;51:7508-13
13. Andreani A, Granaiola M, Leoni A, et al. Potential antitumor agents. 37.1 Synthesis and antitumor activity of guanylhydrazones from imidazo[2,1-b] thiazoles and from the new heterocyclic system thiazolo[2¢,3¢:2,3] imidazo[4,5-c] quinoline. J Med Chem 2005;48:3085-9
14. Andreani A, Burnelli S, Granaiola M, et al. Synthesis and antitumor activity of guanylhydrazones from 6-(2,4-dichloro-5-nitrophenyl)imidazo[2,1-b] thiazoles and 6-pyridylimidazo[2,1-b]thiazoles. J Med Chem 2006;49:7897-01
15. Andreani A, Granaiola M, Locatelli A, et al. Substituted 3-(5-imidazo[2,1-b] thiazolylmethylene)-2-indolinones and analogues: synthesis, cytotoxic activity, and study of the mechanism of action. J Med Chem 2012;55:2078-88
16. Andreani A, Burnelli S, Granaiola M, et al. Substituted E-3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. Effect on the cell cycle and apoptosis. J Med Chem 2007;50:3167-72
17. Andreani A, Granaiola M, Leoni A, et al. Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and study of their effect on the cell cycle1. J Med Chem 2005;48:5604-7
18. Buttar D, Edge M, Luke RWA, et al. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable. Bioorg Med Chem Lett 2008;18:4723-6
19. Park J H, Lee YS, Chang-Hyun OH, et al. New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation and in silico studies. Euro J Med Chem 2011;46:5769-77
20. Kamal A, Sultana F, Bhadra MP, et al. 3-Substituted 2-phenylimidazo[2,1- b] benzothiazoles: synthesis, anticancer activity, and inhibition of tubulin polymerization. ChemMedChem 2012;7:292-300
21. Avila H P, Smania EF, Monache FD, et al. Structure-activity relationship of antibacterial chalcones. Bioorg Med Chem 2008;16:9790-4
22. Syam S, Abdelwahab SI, Mohan S, et al. Synthesis of chalcones with anticancer activities. Molecules 2012;17:6179-95
23. Romagnoli R, Baraldi PG, Preti D, et al. Design, synthesis and biological evaluation of thiophene analogues of chalcones. Bioorg Med Chem 2008;16:5367-76
24. Echeverria C, Santibanez JF, Tagle RR, et al. Structural antitumoral activity relationships of synthetic chalcones. Int J Mole Sci 2009;10:221-31
25. Szliszka E, Czuba ZP, Mazur B, et al. Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells. Int J Mole Sci 2010;11:1-13
26. Ilango K, Valentina P, Saluja G. Synthesis and in-vitro anticancer activity of some substituted chalcone derivatives. Res J Phar Bio Chem Sci 2010;1:354-9
27. Yadav HL, Gupta P, Pawar PS, et al. Synthesis and biological evaluation of antiinflammatory activity of 1,3-diphenyl propenone derivatives. Med Chem Res 2010;19:1-8
28. Zhang XW, Zhao DH, Quan YC, et al. Synthesis and evaluation of anti-inflammatory activity of substituted chalcone derivatives. Med Chem Res 2010;19:403-12
29. Gao X, Deeb D, Gautam S, et al. Immunomodulatory activity of xanthohumol: inhibition of T cell proliferation, cell-mediated cytotoxicity and Th1 cytokine production through suppression of NF-kappaB. Immunopharmacol Immunotoxicol 2009;31:477-84
30. De León EJ, Alcaraz MJ, Dominguez JN, et al. 1-(2,3,4- trimethoxyphenyl)-3-(3-(2-chloroquinolinyl))-2-propen-1-one, a chalcone derivative with analgesic, anti-inflammatory and immunomodulatory properties. Inflamm Res 2003;52:246-57
31. Hamdi N, Fischmeister C, Valerga P, et al. A rapid access to new coumarinyl chalcone and substituted chromeno[4,3-c] pyrazol-4(1H)-ones and their antibacterial and DPPH radical scavenging activities. Med Chem Res 2010;19:1-16
32. Bhatia NM, Mahadik KR, Bhatia MS. QSAR analysis of 1,3-diaryl-2-propen-1- ones and their indole analogs for designing potent antibacterial agents. Chemical Papers 2009;63:456-63
33. Lunardi F, Guzela M, Rodrigues AT, et al. Trypanocidal and leishmanicidal properties of substitution-containing chalcones. Antimicrob Agents Chemother 2003;47:1449-51
34. Lunardi F, Guzela M, Santos AR, et al. Trypanocidal and leishmanicidal properties of substitution-containing chalcones. Antimicrob Agents Chemother 2003;47:1449-51
35. Nielsen SF, Christensen SB, Liljefors T, et al. Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J Med Chem 1998;41:4819-32
36. Motta LF, Gaudio AC, Takahata Y. Quantitative structure-activity relationships of a series of chalcone derivatives (1,3-diphenyl-2-propen-1-one) as anti-Plasmodium falciparum agents (antimalaria agents). Internet Electron J Mol Des 2006;5:555-69
37. Awasthi SK, Mishra N, Kumar B. Sharma et al. Potent antimalarial activity of newly synthesized substituted chalcone analogs in vitro. Med Chem Res 2009;18:407-20
38. Valdameri G, Pietro AD, Boumendjel A, et al. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity. J Med Chem 2012;55:3193-200
39. Lawrence NJ, Patterson RP, Ducki S, et al. Effects of alpha-substitutions on structure and biological activity of anticancer chalcones. Bioorg Med Chem Lett 2006;16:5844-8
40. Ducki S, Woo DRM, Kendall A, et al. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. Bioorg Med Chem 2009;17:7698-10
41. Pettit GR, Singh SB, Hamel E, et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989;45:209-11
42. Lin CM, Ho HH, Pettit GR, et al. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989;28:6984-91
43. Jordan A, Lawrence NJ, McGown AT, et al. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-96
44. Edwards ML, Stemerick DM, Sunkara PS. Chalcones: a new class of antimitotic agents. J Med Chem 1990;33:1948-54
45. Cushman M, Zhu H, Geahlen RL, et al. Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src. J Med Chem 1994;37:3353-62
46. Kumar SK, Hager E, Pettit C, et al. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J Med Chem 2003;46:2813-15
47. Bandgar BP, Gawande SS, Bodade RG, et al. Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents. Bioorg Med Chem 2010;18:1364-70
48. Rao YK, Fang S, Tzeng YM. Synthesis and biological evaluation of 3¢,4¢,5¢-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation. Bioorg Med Chem 2009;17:7909-14
49. Kong Y, Wang K, Brown ML, et al. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg Med Chem 2010;18:971-7
50. Vincenzo DR, Scambia G, Mancuso S, et al. Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity relationships. Anticancer Drug Des 1995;10:481-90
51. Park EJ, Park HR, Kim J, et al. Licochalcone A: an inducer of cell differentiation and cytotoxic agent from Pogostemon cablin. Planta Medica 1998;64:464-6
52. Williams CA, Grayer RJ. Anthocyanins and other flavonoids. Nat Prod Rep 2004;21:539-73
53. Calliste CA, Le Bail JC, Trouillas P, et al. Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities. Anticancer Res 2001;21:3949-56
54. Maggiolini M, Statti G, Vivacqua A, et al. Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J Steroid Biochem Mol Biol 2002;82:315-22
55. Delmulle L, Bellahcène A, DeKeukeleire D, et al. Anti-proliferative properties of prenylated flavonoids from hops (Humulus lupulus L.) in human prostate cancer cell lines. Phytomedicine 2006;13:732-4
56. Colgate EC, Miranda CL, Ho E, et al. Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. Cancer Lett 2007;246:201-9
57. Gerhauser C, Alt A, Becker H, et al. Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. Mol Cancer Ther 2002;11:959-69
58. Plazar J, Zegura B, Lah TT, Filipic M. Protective effects of xanthohumol against the genotoxicity of benzo(a)pyrene (BaP), 2-amino-3-methylimidazo[4,5-f] quinoline (IQ) and tert-butyl hydroperoxide (t-BOOH) in HepG2 human hepatoma cells. Mutat Res 2007;632:1-8
59. Dietz BM, Kang YH, Bolton JL, et al. Xanthohumol isolated from Humulus lupulus Inhibits menadione-induced DNA damage through induction of quinone reductase. Chem Res Toxicol 2005;18:1296-05
60. Albini A, Dell'Eva R, Fassina G, et al. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J 2006;20:527-9
61. Yamazaki S, Morita T, Endo H, et al. Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett 2002;183:23-30
62. Kumar D, Kumar NM, Akamatsu K, et al. Synthesis and biological evaluation of indolyl chalcones as antitumor agents. Bioorg Med Chem Lett 2010;20:3916-19
63. Lawrence NJ, McGown AT, Ducki S, et al. The interaction of chalcones with tubulin. Anticancer Drug Des 2000;2:135-41
64. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98
65. Aggarwal BB, Sundaram C, Malani N, et al. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1-75
66. Adams BK, Snyder JP, Shoji M, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004;12:3871-83
67. Lagisetty P, Vilekar P, Awasthi V, et al. CLEFMA-an anti-proliferative curcuminoid from structure-activity relationship studies on 3,5-bis (benzylidene)-4-piperidones. Bioorg Med Chem 2010;18:6109-20
68. Rizzo S, Bartolini M, Rampa A, et al. Targeting Alzheimer's disease: novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorg Med Chem 2010;18:1749-60
69. Dimmock JR, Zello GA, Oloo EO, et al. Correlations between cytotoxicity and topography of some 2-arylidenebenzocycloalkanones determined by X-ray crystallography. J Med Chem 2002;45:3103-11
70. Juvale K, Pape VF, Wiese M. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Bioorg Med Chem 2012;20:346-55
71. Zuo Y, Yu Y, Bu X, et al. Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNFa-induced nuclear factor-kB activation inhibition Euro J Med Chem 2012;50:393-04
72. Mielcke TR, Mascarello A, Campos M, et al. Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation. Euro J Med Chem 2012;48:255-64
73. Vogel S, Barbic M, Heilmann J, et al. Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of A-ring modifications on the pharmacological effect. Euro J Med Chem 2010;45:2206-13
74. Nagaraju M, Deepthi GE, Gawali B.B, et al. Synthesis and selective cytotoxic activity of novel hybrid chalcones against prostate cancer cells. Bioorg Med Chem Lett 2012;22:4314-17
75. Singh P, Kumar V, Saxena AK, et al. 1,2,3-Triazole tethered b-lactam-Chalcone bifunctional hybrids: Synthesis and anticancer evaluation. Euro J Med Chem 2012;47:594-00
76. Bours V, Bentires-Alj M, Hellin AC, et al. Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 2000;60:1085-9
77. Sun Z, Andersson R. NF-kappaB activation and inhibition: shock. 2002;2:99-06
78. Viatour P, Merville MP, Chariot A, et al. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005;1:43-52
79. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system a molecular target in breast cancer therapy. J Surg Res 2005;123:158-69
80. Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci 2008;99-836.42
81. Shen KH, Chang JK, Kuo PL, et al. Chalcone arrests cell cycle progression and induces apoptosis through induction of mitochondrial pathway and inhibition of nuclear factor kappa B signalling in human bladder cancer cells. Basic Clin Pharmacol Toxicol 2007;101:254-61
82. Pandey MK, Sandur SK, Aggarwal BB, et al. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J Biol Chem 2007;282:17340-50
83. Lorenzo P, Alvarez R, Ortiz MA, et al. Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids. J Med Chem 2008;51:5431-40
84. Kamal A, Shankaraiah N, Reddy RCH, et al. Solid-phase synthesis of new pyrrolobenzodiazepine-chalcone conjugates: DNA-binding affinity and anticancer activity. Bioorg Med Chem Lett 2008;18:2434-9
85. Kamal A, Prabhakar S, Bhadra MP, et al. Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers. Euro J Med Chem 2011;46:3820-31
86. Kamal A, Ramakrishna G, Viswanath A, et al. Synthesis and anti-cancer activity of chalcone linked imidazolones. Bioorg Med Chem Lett 2010;20:4865-9
87. Kamal A, Mallareddy A, Suresh P, et al. Synthesis of chalcone- amidobenzothiazole conjugates as antimitotic and apoptotic inducing agents. Bioorg Med Chem 2012;20:3480-92
88. Kumar SK, Hager E, Khan SR, et al. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J Med Chem 2003;46:2813-15
89. Kamal A, Dastagiri D, Reddy JS, et al. Synthesis of imidazothiazole- chalcone derivatives as anticancer and apoptosis inducing agents. ChemMedChem 2010;5:1937-47